Tysabri linked to new infection

Biogen Idec and Elan have been hammered yet again by reports linking Tysabri to a deadly form of brain cancer. The Wall Street Journal reports that a possible fifth case of PML has been discovered. Their stock had been recovering based on optimistic projections that the two drug developers could create an acceptable strategy for returning the therapy to market while monitoring patients for symptoms of PML. Some analysts say that appears to be increasingly unlikely as more cases of possible PML are reported. Tysabri had been on its way to becoming the leading treatment for multiple sclerosis when it was withdrawn after two cases of PML were confirmed.

- read this story from Businessworld for more

Suggested Articles

A new clinical hold is the latest setback for Solid Biosciences and the development of its gene therapy for Duchenne muscular dystrophy.

VBI's Sci-B-Vac protected twice as many people than GSK's Engerix-B did after the second dose.

The notice comes weeks after Amgen revealed it was retreating from its East Coast neuroscience operations.